Author: Stéphanie BELLAVIA

RMS Medical Devices Announces Strategic Commercial Partnership with Avicenna.AI in the Benelux Region

Belgium — March, 2025 – RMS Medical Devices, a leader in innovative medical technologies, is excited to announce a strategic commercial partnership with Avicenna.AI, a global pioneer in artificial intelligence (AI) solutions for medical imaging. This partnership aims to bring cutting-edge AI-powered diagnostic tools to healthcare providers in Belgium, the Netherlands, and Luxembourg (Benelux), enhancing patient care and operational efficiency across the region.
Transforming Medical Imaging with AI
Avicenna.AI’s advanced AI algorithms enable faster and more accurate detection of critical pathologies in medical imaging. These include the automated identification of acute stroke (ischemic and hemorrhagic), detection of large vessel occlusions, subdural hematomas, pulmonary embolisms, aortic dissections, and other life-threatening conditions, ensuring timely and precise diagnostics in emergency and routine care. By integrating these innovative solutions into the Benelux market, RMS
Medical Devices reinforces its commitment to delivering high-quality, value-driven healthcare
technologies that empower medical professionals and improve patient outcomes.
A Synergistic Partnership
The collaboration between RMS Medical Devices and Avicenna.AI is a strategic move to address the growing demand for intelligent diagnostic tools in the Benelux region. With RMS’s strong local expertise and established network of healthcare professionals, coupled with Avicenna.AI’s state-of- the-art technology, this partnership is set to revolutionize diagnostic workflows and optimize resource utilization in hospitals and clinics. RMS Medical Devices has extensive expertise in the clinical and commercial implementation of Medical Imaging AI, built upon its deep insights into local clinical workflows and the value-added support it provides to ensure successful adoption and integration of advanced technologies.
“We are thrilled to partner with Avicenna.AI to introduce their transformative AI solutions to the Benelux market,” said Olivier Wouters, Business; Product Development Director at RMS Medical Devices. “This partnership aligns perfectly with our mission to bring innovative, patient-focused technologies to healthcare providers. We believe that Avicenna.AI’s solutions will significantly enhance diagnostic accuracy and speed, ultimately saving lives.”
“Partnering with RMS Medical Devices is a natural fit for Avicenna.AI as we expand our reach in the European market,” said Martijn Jonkers, VP of Sales and Marketing EMEA of, Avicenna.AI. “RMS’s deep understanding of the Benelux healthcare landscape and their commitment to innovation make them an ideal partner to bring our AI-powered solutions to more hospitals and imaging centers.”
Availability and Implementation
The partnership’s first phase will focus on deploying Avicenna.AI’s solutions in key hospitals and radiology centers across the Benelux region. RMS Medical Devices will provide comprehensive support, including training and ongoing service, to ensure seamless integration of the AI tools into existing clinical workflows.
About RMS Medical Devices
RMS Medical Devices is a trusted provider of innovative medical technologies and solutions, dedicated to improving patient outcomes and empowering healthcare professionals. With a strong presence in the Benelux region, RMS collaborates with global leaders to bring the latest advancements in medical science to local markets.
About Avicenna.AI
Avicenna.AI is a global leader in artificial intelligence for medical imaging, offering groundbreaking solutions that enhance the speed and accuracy of diagnostics. By leveraging the power of AI, Avicenna.AI empowers healthcare providers to deliver better care and improve patient outcomes.

13/03/2025
Viz.ai Integrates Avicenna.AI’s Tools for ASPECTS Stroke Severity Assessment and Incidental Pulmonary Embolism into Viz.ai One Platform

SAN FRANCISCO – December 16, 2024 –Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Avicenna.AI, a leading provider of AI-based medical imaging solutions, today announced that Viz.ai is integrating Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai One™ platform. The combination of Avicenna’s two AI-based algorithms with Viz.ai’s care coordination capabilities provides radiologists and specialists with additional insights from computed tomography (CT) scans, to advance fast and accurate decision-making, driving better patient care.
“This expanded partnership with Avicenna.AI represents an important step forward in our mission to improve patient care through AI-powered, clinical workflows,” said Justin Ryea, director of product at Viz.ai. “By integrating CINA-iPE and CINA-ASPECTS into Viz.ai One, we are providing clinicians with an even more robust, all-in-one neurovascular solution that they can trust. This can help speed up the decision-making process and ensure that patients receive appropriate treatment as quickly as possible.”
The CINA-ASPECTS tool automatically assesses the ASPECTS (Alberta Stroke Program Early CT Score) from CT brain images, providing an objective and reliable measure of stroke severity. Avicenna received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CINA-iPE and CINA-ASPECTS tools in March 2024. The CINA-iPE tool detects incidental pulmonary embolism (PE), a life-threatening blockage in a lung artery, during routine CT scans and is intended to address delayed and missed findings. Unsuspected PE is a common finding in routine CT scans of the chest, but as little as 25% of emboli are reported during the initial interpretation¹. By combining Avicenna.AI’s technology with Viz.ai One, which facilitates real-time communication and coordination among care teams, clinicians can make faster, more informed decisions about treatment options for patients in need.
“We are thrilled to further our partnership with Viz.ai,” said Cyril Di Grandi, CEO of Avicenna.AI. “Incorporating CINA-iPE and CINA-ASPECTS into Viz.ai’s platform will allow us to bring a higher level of quality and efficiency to patient care. Our shared goal of empowering healthcare professionals with innovative tools to make critical decisions quickly and confidently can improve outcomes for more patients by helping to diagnose life-threatening conditions faster and facilitating appropriate follow-up care to patients when they need it.”
¹ Gladish GW, Choe DH, Marom EM, Sabloff BS, Broemeling LD, Munden RF. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology. 2006 Jul;240(1):246-55. doi: 10.1148/radiol.2401051129. Epub 2006 May 9. PMID: 16684921.

17/12/2024
Integrating Avicenna.AI into the teleradiology workflow: Feedback from TIM smooth integration into clinical practice
Our teleradiology workflow is based on systematic, near real-time analysis using Avicenna.AI’s tools for analyzing CT scan exams performed in our partner establishments, in both scheduled and emergency workflows.
In typically scheduled workflows, the radiologist’s interpretation can occur retrospectively, even after the patient has left the department. AI analysis serves as an initial assessment tool, providing essential support in identifying urgent cases and streamlining patient care. This initial AI analysis is crucial for prioritizing examinations and allowing for immediate interpretation by a radiologist when required.
Every alert generated by the AI is promptly validated by a radiologist, regardless of the examination workflow (scheduled or urgent), ensuring a reliable and precise diagnosis.
The integration of AI, especially in scheduled activities, facilitates real-time adaptation of patient care by prioritizing examination interpretation as needed.
The graph below demonstrates the effectiveness of AI in this process, using statistics from a representative sample collected over one month of activity:

Key results
Overall reliability
The AI generated 359 alerts, most of which (285) were confirmed as correct. This underlines Avicenna’s AI’s effectiveness in identifying relevant real-time anomalies.
Incidental findings
29 alerts led to unexpected findings, demonstrating the value of exhaustive analysis in detecting secondary pathologies that are often overlooked. These findings considerably enrich our contribution to comprehensive patient care.
Managing false positives
The 45 false positives identified, mostly linked to technical artifacts (e.g. inadequate injection time), were corrected thanks to human review. This supervision ensures that patient care remains at the highest level of quality.
Enhanced workflow with AI
Integrating AI into our workflow has allowed us to achieve several key objectives:
Improved Efficiency: Rapid identification of examinations that require special attention.
Enhanced Quality: Expanded detection of anomalies, including unexpected findings.
Resource Optimization: Reduced time required for the radiologist’s preliminary reading.
We are very pleased with the integration of Avicenna.AI into our teleradiology workflow. This demonstrates the concrete value of artificial intelligence as a complementary tool to human expertise, paving the way for faster, more accurate, and proactive healthcare
About TIM:
Founded in 2016, TIM is a committed company that positions itself as an essential partner in teleradiology for public and private healthcare institutions in France. Its mission is to provide and organize high-quality teleradiology services for scheduled activities and emergency PDS/CDS (day/night). TIM holds two Resah contracts for managing its activities (2022-055 lot 1 and lot 2). By offering a team of qualified experts and innovative technologies, TIM ensures fast and accurate diagnoses, making medical imaging accessible everywhere, for everyone.
www.teleimagerie.net
Press contact:
Cédric MUNSCHY
Commercial Director
+33 (0)2 85 52 90 60 / communication@teleimagerie.net
21/11/2024
Avicenna.AI secures Medical Device Regulation certification for medical imaging AI portfolio

French AI company achieves key EU regulatory compliance for multiple algorithms that identify, detect, and quantify severe conditions from medical images.
La Ciotat, FRANCE – July 3, 2024 – Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company’s product portfolio is fully compliant with the European Union’s MDR 2017/745, which is now mandatory for medical device companies that want to provide their solutions in Europe.
The MDR was introduced to update the EU’s regulations for medical devices, addressing safety issues and the recent emergence of AI tools and software as a medical device (SaMD), which did not exist when the old regulations were created. Ensuring MDR compliance is a critical component of obtaining and maintaining CE-mark status, which allows a device to be freely traded in the EU.
Compared to the previous Medical Device Directive (MDD), the MDR has a wider scope and more stringent requirements. It emphasizes clinical evaluation, post-market surveillance, device traceability, rigorous technical documentation, and risk management. These measures aim to enhance patient safety and ensure high standards for medical devices, including AI and software-based solutions.
Avicenna.AI’s products have been certified as Class IIb medical devices, which requires a high level of clinical validation. The certified products include the company’s suite of AI tools for neurovascular conditions, as well as its suite of algorithms for vascular conditions.
“Obtaining MDR certification is a significant milestone for Avicenna.AI. It demonstrates our commitment to meeting the highest standards of medical device safety and performance. This certification not only reinforces our dedication to compliance but also assures our customers of the quality and reliability of our AI product portfolio,” said Stéphane Berger, Regulatory Manager at Avicenna.AI.
The company’s MDR-certified AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), quantification of stroke severity (CINA-ASPECTS), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and opportunistic cases of pulmonary embolism (CINA-iPE). All the products are also CE-marked and FDA-cleared.
“Crucially, despite the differences in SaMD regulatory requirements between authorities in the US and Europe, we are consistently achieving both FDA and CE mark clearance for our AI products,” added Berger.
All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

03/07/2024
$Avicenna.AI secures FDA clearance for AI detection of vertebral compression fractures$

Avicenna.AI secures FDA clearance for AI detection of vertebral compression fractures

Medical imaging AI company receives approval for algorithm enabling opportunistic detection and triage of vertebral compression fractures.
La Ciotat, FRANCE – June 12, 2024 – Avicenna.AI, a leading medical imaging AI company, has received 510(k) clearance from the US Food and Drug Administration (FDA) for CINA-VCF, a triage and notification AI tool that detects unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans.
Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In the USA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but around two-thirds of those go undetected or unreported.
The CINA-VCF algorithm identifies and prioritizes vertebral compression fractures detected during routine CT scans for patients undergoing medical imaging for entirely different health conditions, notifying clinicians within seconds. The tool was validated on 474 CT scans (performed for other clinical indications than for VCF evaluation) acquired on 38 different scanner models from four different manufacturers, achieving excellent sensitivity and specificity results.
By facilitating the early detection of vertebral compression fractures, CINA-VCF aims to help prevent further bone density loss and additional fractures, enhancing patient care and outcomes. The tool enables vertebral fractures to be addressed before they multiply, reducing the risk of complications and potentially lowering medical expenses.
“Osteoporosis is a global burden affecting millions, especially postmenopausal women, and often goes unnoticed until symptoms like pain and loss of mobility appear,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “By detecting vertebral compression fractures early, we aim to help patients maintain better mobility and independence, enhance the well-being of those at risk, and reduce the burden on healthcare systems worldwide. We have also partnered with the International Osteoporosis Foundation to increase awareness about this debilitating condition.”
CINA-VCF is the latest tool from Avicenna.AI to secure FDA clearance, joining its AI solutions for automatic detection of a host of conditions from CT imaging. It is also the company’s second tool FDA-cleared for incidental findings, alongside CINA-iPE, which identifies unsuspected cases of pulmonary embolism in oncology patients.
The company’s other AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and quantification of stroke severity (CINA-ASPECTS). All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists

12/06/2024
Avicenna.AI secures two FDA clearances for Stroke Assessment and opportunistic PE

La Ciotat, FRANCE – March 26, 2024 – Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
Addressing the serious issue of delayed and missed findings in diagnostic imaging, CINA-iPE is an AI-powered tool that detects incidental pulmonary embolism during routine CT scans. Unsuspected pulmonary embolism is a common finding in routine CT scans of the chest, but as little as 25% of emboli are reported during the initial interpretation. This is particularly relevant in the cancer patient population, where pulmonary embolism is a significant cause of mortality.
The CINA-iPE algorithm identifies lung blood clots detected during routine CT scans for entirely different health conditions. Scan types may include full-body scans, scans of the chest, abdomen, and pelvis, and scans of the thoracic area along with the abdomen and pelvis. The tool was validated on 381 CT scans (performed for other clinical indications than for pulmonary embolism evaluation) acquired on 39 different scanner models from five leading manufacturers, achieving excellent sensitivity and specificity.
“From day one, we have been committed to validating our AI tools on every type of CT scanner,” said Yasmina Chaibi, Clinical Affairs Manager, Avicenna.AI. “In our validation studies, CINA-iPE achieved excellent sensitivity and specificity, demonstrating its ability to provide effective prioritization and triage on routine CT scans performed for other clinical indications than pulmonary embolism suspicion.”
CINA-ASPECTS is an AI tool for stroke severity assessment, automatically processing non-contrast CT scans and calculating the “ASPECT” score, a topographic scoring system used to quantify the severity of a stroke from a CT scan of the brain. The tool computes a heat map indicating the probability of hypodensity and sulcal effacement in the brain, displays a list of infarcted regions, and provides CT images corrected from tilt to easily compare the right and left hemisphere.
In addition to assisting clinicians in the evaluation of the ASPECT score from CT scans, CINA-ASPECTS also helps improve physicians’ reproducibility in ASPECT scoring, which often varies depending on the radiologist reading the scan. The tool was rigorously validated on 200 scans acquired on 27 scanner models from four leading manufacturers.
“The validations and multi-reader-multi-case studies we conducted highlighted that CINA-ASPECTS not only obtained outstanding standalone performance, but also demonstrated that its adjunctive use significantly improved clinicians’ accuracy in the assessment of ASPECTS regions, compared to the conventional use of NCCT images alone,” added Chaibi.
CINA-ASPECTS is the first FDA-cleared tool from Avicenna.AI in the category of computer-aided diagnosis (CADx), which means it goes beyond identifying abnormalities in scans to provide an assessment of the severity of a condition.
“We are delighted to launch CINA-ASPECTS to the US market, marking a significant milestone as our first CADx product receives FDA clearance,” said Stéphane Berger, Regulatory and Quality Manager. “We take pride in being at the forefront of CADx solutions, being the first AI company supported by thorough clinical validation and a rich repository of real-world clinical data, which ensures compatibility across all manufacturers and platforms.”
CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging. All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
“After a long journey of dedication and perseverance, we are thrilled to announce the FDA clearance of not one, but two of our groundbreaking products,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care. These achievements stand as a testament to the unwavering commitment of our team.”

26/03/2024
Blackford integrates CINA-iPE for opportunistic pulmonary embolism detection

La Ciotat, FRANCE – February 15, 2024 – Avicenna.AI, a French medical imaging AI specialist, is proud to announce a strategic partnership with AI platform pioneers Blackford to integrate its CINA-iPE, a CE-marked solution, into the Blackford AI Platform. This collaboration represents a significant step forward in the field of healthcare AI, offering healthcare professionals enhanced capabilities for detecting incidental pulmonary embolism during routine CT scans.
Blackford provides healthcare professionals access to an extensive portfolio of more than 115 AI solutions designed to drive clinical efficiencies and improve patient outcomes. By integrating Avicenna’s CINA-iPE solution into the Blackford Platform, Blackford enhances their ability to provide healthcare professionals with a powerful tool for identification of lung blood clots in Chest CT Angiography.
Incidental pulmonary embolism is a common finding in routine CT scans of the chest, with only 25% of incidental emboli reported during the initial interpretation*. Addressing the serious issue of delayed and missed findings in diagnostic imaging, this partnership aims to significantly impact patient outcomes, particularly in the cancer patient population where incidental pulmonary embolism is a major cause of mortality.
“Blackford is always looking to enhance our AI portfolio to provide healthcare professionals with innovative tools to help enhance clinical efficiency and decision making”, said Ben Panter, Founder and CEO of Blackford. “We’re delighted to add the CINA-iPE pulmonary embolism solution to our platform, further enhancing our existing trusted relationship with Avicenna.AI”
“We are thrilled to empower the extensive community of Blackford users with our innovative incidental Pulmonary Embolism algorithm. This global partnership brings healthcare providers closer to a more systematic reporting and treatment of life-threatening pulmonary emboli,” stated Cyril Di Grandi, Co-founder, and CEO of Avicenna. AI.
References
* https://pubmed.ncbi.nlm.nih.gov/16684921/
About Avicenna.AI
Avicenna.AI, founded in 2018, specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify life-threatening pathologies from CT medical images. Co-founded by Cyril Di Grandi, a successful entrepreneur who previously co-founded Olea Medical, and Dr. Peter Chang, an internationally recognized radiologist, and an expert in AI and deep learning, Avicenna.AI aims to accelerate therapeutic decision-making processes and enhance patient outcomes through its AI-based radiology solutions. For additional details, stay connected with us on social media and explore Avicenna.AI’s website at www.avicenna.ai. Delegates attending ECR 2024 can learn more by scheduling a meeting with the Avicenna.AI team during the event using the following link: https://bit.ly/avicennaecr2024.
For more information, contact:
Stéphanie Bellavia, Marketing Manager
Email: stephanie.bellavia@avicenna.Ai

About Blackford
Blackford are pioneers in the radiology AI space, with over a decade of experience working in partnership with leading hospitals and ground-breaking technology providers. We operate as a strategic AI partner, providing access to a tried-and-tested core platform, tailored services, and a portfolio of 100+ applications to help healthcare providers unlock the value of AI and improve patient outcomes.
Our collaboration and recent arms-length acquisition by Bayer ensures that our customers and partners have the support and long-term security needed to underpin successful AI strategies. To learn more about Blackford’s tailored approach to AI solutions visit www.blackfordanalysis.com, and follow us on X and LinkedIn.
For more information, contact:
Nick Cole, VP Marketing, Blackford
Email: nick.cole@blackfordanalysis.com
Phone: +44 7812164790

15/02/2024
ConcertAI’s TeraRecon partners with Avicenna.AI for AI-driven chest care coordination.

CAMBRIDGE, Mass., 01/11/2023 – ConcertAI’s TeraRecon, a leader in advanced visualization and AI Clinical SaaS, is pleased to announce an expanded collaboration with Avicenna.AI, a specialist in medical imaging AI. Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD). This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
Diagnosing and coordinating care for patients facing PE and AD pose significant hurdles. Avicenna.AI has FDA approval for its algorithms, tailored for PE and both Type A and Type B AD, which will seamlessly integrate into the Eureka Clinical AI platform. This integration aims to streamline identification of these conditions, thus empowering multidisciplinary patient care coordination. Upon detecting a PE or AD, the Eureka Clinical AI platform will rapidly notify each provider’s desktop or mobile device, delivering dynamic imaging and comprehensive patient information. Additionally, the aortic module offering will grant access to imaging and workflows supporting coordinated care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis, and transection, alongside the AD algorithm. Likewise, the PE algorithm will be accessible through the Eureka Clinical AI platform’s PE module.
The inclusion of AI-powered workflows via the Eureka Clinical AI platform is anticipated to significantly reduce the time it takes a physician to diagnose these potentially life threating conditions to treatment by facilitating more informed treatment decisions across health systems.
Through the incorporation of Avicenna’s PE and AD solutions, coupled with the existing CINA-iPE on the Eureka Clinical AI platform for the EU, TeraRecon is positioned to offer enhanced pulmonary and aortic solutions to its global clientele of approximately 1,900 customers.
“We are dedicated to expanding the Eureka Clinical AI ecosystem with impactful AI solutions that support our clinicians and care providers,” said Dan McSweeney, President of TeraRecon. “Avicenna’s solutions play a crucial role in fulfilling this commitment by broadening access to essential triage capabilities through our scalable Eureka Clinical AI platform.”
Avicenna.AI specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify life-threatening pathologies from CT images. By employing a blend of deep learning and machine learning technologies, the company’s solutions autonomously detect and prioritize emergency cases within seconds, assess their severity, and promptly notify radiologists.
“We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection,” said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI. “Our aim is to expedite an optimal medical response within a short timeframe and enhance patient care. We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond.”
Eureka Clinical AI stands as the foremost AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. Distinguished as the industry’s most widely deployed platform, it uniquely accommodates third-party AI algorithms, facilitating consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can swiftly access results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management, and coordinated care delivery.
To learn more about the Eureka Clinical AI platform, its capabilities, and algorithms spanning neurology, radiology, cardiology, oncology, and more, visit: https://www.terarecon.com/artificial-intelligence.
About TeraRecon: Serving approximately 1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at www.terarecon.com
About ConcertAI: ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at http://www.concertai.com or follow us on LinkedIn.
About Avicenna.AI: Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai

07/11/2023
ConcertAI’s TeraRecon and Avicenna.AI Partner on AI for Incidental Pulmonary Embolism

Medical imaging AI companies collaborate to offer CINA-iPE on TeraRecon’s Eureka Clinical AI platform.
Cambridge, Mass., March 13, 2023 – ConcertAI’s TeraRecon, the advanced visualization and AI Clinical SaaS category leader, today announced a partnership to offer medical imaging AI specialist Avicenna.AI‘s CINA-iPE solution detecting the presence of incidental pulmonary embolisms as part of TeraRecon’s Eureka Clinical AI solution. Eureka Clinical AI and Intuition are KLAS top-rated solutions for clinical AI and advanced visualization.
Incidental pulmonary embolism is a frequent finding on routine CT scans of the chest, but only 25% of incidental emboli are reported at the initial interpretation. CINA-iPE is a CE-marked AI tool that analyzes images from CT scans and detects the presence of incidental pulmonary embolism immediately and with great immdiat consistency and accuracy. Delayed and missed findings are some of the most serious problems in diagnostic imaging, and incidental pulmonary embolism is a significant cause of mortality in the cancer patient population.
“We are committed to expanding the Eureka Clinical AI ecosystem with meaningful AI solutions to support our clinicians and care providers. Avicenna’s incidental pulmonary embolism detection algorithm is just one example of this commitment. This unique solution expands access to this critical diagnostic capability via our scalable Eureka Clinical AI platform,” said Dan McSweeney, President of TeraRecon.
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, assess them for severity, and then seamlessly alert radiologists.
“We are delighted to empower the wide community of TeraRecon users with our innovative incidental pulmonary embolism AI algorithm. This global partnership brings healthcare providers closer to a more systematic reporting and treatment of life-threatening pulmonary emboli,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI.
Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. As the industry’s most broadly deployed platform, it is unique in that it is open to third-party AI algorithms, allowing consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can see results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management and coordinated care delivery.
Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence
About ConcertAI: ConcertAI is the leader in AI Saas Technologies for clinical research and clinical care and Real-World Evidence (RWE) solutions. Our mission is to accelerate insights and biomedical innovations, thereby improving outcomes for patients. For more information, visit us at www.concertai.com
About TeraRecon: Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at www.terarecon.com
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai

15/03/2023
Avicenna.AI launches AI solution for incidental pulmonary embolism detection

Medical imaging company to introduce CINA-iPE – the first tool in its new AI suite for incidental findings – at ECR 2023.
Marseille, FRANCE – February 22, 2023 – Medical imaging AI specialist Avicenna.AI today announced the launch of CINA-iPE, a CE-marked AI tool that analyzes images from CT scans for the presence of incidental pulmonary embolism. CINA-iPE is the first tool in CINA Incidental, a new suite of medical imaging solutions from Avicenna.AI that detect unsuspected pathologies on CT scans.
Avicenna.AI will demonstrate CINA-iPE for the first time at the European Congress of Radiology, March 1 – 5, 2023.
Incidental pulmonary embolism is a frequent finding on routine CT scans of the chest, but only 25% of incidental emboli are reported at the initial interpretation. Delayed and missed findings are some of the most serious problems in diagnostic imaging, and incidental pulmonary embolism is a significant cause of mortality in the cancer patient population.
CINA Incidental sits alongside the company’s existing suite, CINA ER, which includes a range of FDA-cleared and CE-Marked tools for neurovascular and thoraco-abdominal emergencies. All of Avicenna.AI’s AI tools are seamlessly integrated within clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
“If pathologies are visible on a CT scan, the technology now exists to detect them – helping clinicians reduce time-to-treatment and save lives,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “Our CINA Incidental suite helps healthcare professionals detect incidental findings in patients receiving imaging for entirely different health conditions, improving patient care and outcomes. The launch of CINA-iPE is the first step in a new direction for Avicenna.AI. Pulmonary embolism is a dangerous, life-threatening condition, and with CINA-iPE we hope to increase the number of patients identified with incidental PE and help improve their outcomes.”
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, and assess them for severity, before seamlessly alerting radiologists.
ECR 2023 delegates can find out more at the Avicenna.AI booth (AI-25).

22/02/2023